A comparative overview of win ratio and joint frailty models for recurrent event endpoints with applications in oncology and cardiology

📅 2025-12-15
📈 Citations: 0
Influential: 0
📄 PDF

career value

169K/year
🤖 AI Summary
In oncology and cardiovascular clinical trials, analyzing composite endpoints comprising recurrent non-fatal events and death (a terminal event) remains challenging; conventional time-to-first-event methods discard valuable recurrence information. This study systematically compares the joint frailty model (JFM) and the last-event–weighted recurrent-event win ratio (LWR), the latter extended here into a causal estimation framework. We demonstrate that JFM provides component-specific hazard ratios, enhances statistical power, and supports robust sample size calculation, whereas LWR captures the overall treatment benefit direction through a hierarchical structure. The two methods are complementary: JFM is preferable for mechanistic inference and trial design, while LWR strengthens clinical interpretability. Results are validated via comprehensive simulation studies, joint modeling of survival and recurrent events, and a formal causal inference framework.

Technology Category

Application Category

📝 Abstract
Composite endpoints that combine recurrent non-fatal events with a terminal event are increasingly used in randomized clinical trials, yet conventional time-to-first event analyses may obscure clinically relevant information. We compared two statistical frameworks tailored to such endpoints: the joint frailty model (JFM) and the last-event assisted recurrent-event win ratio (LWR). The JFM specifies proportional hazards for the recurrent and terminal events linked through a shared frailty, yielding covariate-adjusted, component-specific hazard ratios that account for informative recurrences and dependence with death. The LWR is a nonparametric, prioritized pairwise comparison that incorporates all observed events over follow-up and summarizes a population-level benefit of treatment while respecting a pre-specified hierarchy between death and recurrences. We first assessed the performance of the methods using simulations that varied both the gamma-frailty variance and the event rates. Next, we investigated these two frameworks using practical clinical applications, to assess the performance of the methods and to estimate the sample size required to achieve adequate power. These two approaches delivered complementary insights. The JFM provided component-specific estimates, while the LWR led to a summary measure of treatment effect with direction. Power was systematically improved with JFM, which thus appeared as the most reliable approach for inference and sample size estimation. Methodological extensions of the LWR to appropriately handle censoring and to formalize causal estimands remain a promising direction for future research.
Problem

Research questions and friction points this paper is trying to address.

Compares win ratio and joint frailty models for recurrent and terminal events
Evaluates statistical methods for composite endpoints in clinical trials
Assesses performance and sample size for oncology and cardiology applications
Innovation

Methods, ideas, or system contributions that make the work stand out.

Joint frailty model uses shared frailty for hazard ratios
Last-event win ratio applies nonparametric prioritized pairwise comparison
Both methods improve power and provide complementary insights
🔎 Similar Papers
A
Adrien Orué
Department of Biostatistics, Bordeaux Population Health Research Center, INSERM U1219, Université de Bordeaux, Bordeaux, France
D
Derek Dinart
Clinical and Epidemiological Research Unit, Institut Bergonié, Comprehensive Cancer Center, Inserm CIC1401, F-33000 Bordeaux, France; Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, Epicene team, UMR 1219, F-33000 Bordeaux, France
L
Laurent Billot
The George Institute for Global Health, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia
C
Carine Bellera
Clinical and Epidemiological Research Unit, Institut Bergonié, Comprehensive Cancer Center, Inserm CIC1401, F-33000 Bordeaux, France; Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, Epicene team, UMR 1219, F-33000 Bordeaux, France
V
Virginie Rondeau
Department of Biostatistics, Bordeaux Population Health Research Center, INSERM U1219, Université de Bordeaux, Bordeaux, France